Rapamycin, a drug currently undergoing clinical studies at Columbia University, could delay ovary aging and, in turn, delay menopause, while also reducing future symptom severity.
The Columbia clinical study marks the primary time the drug has been tested on humans, because it has previously been tested on animals at several clinics, which showed that it could extend lifespan and slow aging. The trial, led by Dr. Zev Williams, chief of the division of reproductive endocrinology and infertility at Columbia University Fertility Center, and Dr. Yousin Suh, director of the reproductive aging program at Columbia, is a randomized, double-blind, placebo-controlled study taking a look at the consequences of weekly low dose rapamycin on women ages 35 to 42 over the course of three...
Continue reading
0 Comments
